UNSPSC 51422435: Hydrocortisone tebutate

This classification denotes an anti-inflammatory agent C27H40O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FXJ67LWZ4S, chemically known as cortisol, 21-(3,3-dimethylbutyrate), but more generally known as hydrocortisone tebutate, which bears US NIH Compound Identifier 23424017. Most nations, for tariff and trade purposes, schedule hydrocortisone tebutate under HS 29372100 and SITC 54153. As of Q4 2014, HYDROCORTISONE TEBUTATE remains US FDA's Preferred Term for this commodity.

SMILES: C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2[C@H](C[C@]4([C@H]3CC[C@@]4(C(=O)COC(=O)CC(C)(C)C)O)C)O.

UNSPSC 51422435 Hydrocortisone tebutate is a Commodity code that captures pharmaceutical products procured by state and local health agencies, but the recent opportunities in the source show little direct purchasing activity under this specific drug code. Instead, the two recent solicitations involve broader pharmaceutical procurement mechanisms—naloxone and drug deactivation systems (a different therapeutic category), and a request for information exploring direct-to-manufacturer prescription contracting models. The code nominally describes a corticosteroid medication used in topical and injectable formulations, yet state and local governments that solicit under it appear to be buying through consolidated pharmacy benefit programs, emergency-response drug acquisitions, or exploratory contracting structures rather than purchasing hydrocortisone tebutate as a line item in typical competitive bids.

Recent activity comes from Seminole County, Florida (an IFB for naloxone and drug deactivation systems posted June 30, 2026, due July 26, 2023, for quarterly annual deliveries of 1,900 units of naloxone and 800 deactivation systems) and the Texas Health and Human Services Commission (an RFI posted April 3, 2026, seeking vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements). The geographic spread reflects Florida and Texas activity, though the Texas solicitation is exploratory rather than a competitive procurement. Neither opportunity directly names hydrocortisone tebutate procurement, suggesting the code may see minimal standalone purchasing volume at state and local level, or that health agencies tag hydrocortisone purchases under higher-tier pharmaceutical family codes rather than this specific commodity code.